Patent · US Active

Soluble TNF receptors and their use in treatment of disease

US7785834B2 · kind B2 · utility

0Cited by

19References

6Claims

0Family size

Assignees

Ercole Biotech, Inc. · US
The University of North Carolina at Chapel Hill · US
Santaris Pharma A/S · DK

Inventors

Peter L. Sazani · Bothell, US
Maria Graziewicz · Chapel Hill, US
Ryszard Kole · Chapel Hill, US
Henrik Ørum · Neubiberg, DE

Key dates

Filing date	May 1, 2007
Grant date	Aug 31, 2010
Priority date	—
Expiry date	May 1, 2027

Classification

Technology area (CPC Y)Emerging Cross-Sectional Technologies
CPC primaryY02A50/30
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to tumor necrosis factor (TNF) antagonists and corresponding nucleic acids derived from tumor necrosis factor receptors (TNFRs) and their use in the treatment of inflammatory diseases. These proteins are soluble secreted decoy receptors that bind to TNF and prevent TNF from signaling to cells. In particular, the proteins are mammalian TNFRs that lack exon 7 and which can bind TNF and can act as a TNF antagonist.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.